Randomized controlled trial: Moxibustion and acupuncture for the treatment of Crohn's disease

Crohn's disease is an inflammatory bowel disease affecting thousands of people in Brazil and worldwide, causing debilitating symptoms such as abdominal pain, diarrhea, and fatigue. Although conventional treatments include anti-inflammatory drugs and immunosuppressants, many patients experience significant adverse effects and frequent relapses. In China, where the incidence of Crohn's disease has been rising steadily, researchers have investigated alternative therapies, particularly acupuncture and moxibustion, which have been part of traditional Chinese medicine for more than 4,000 years. Despite the growing use of these therapies for gastroenterological diseases, an important gap existed in the scientific literature regarding their actual efficacy in treating Crohn's disease.

This study was a randomized controlled trial — considered the gold standard in medical research — conducted between January 2010 and April 2013 in China. The investigators recruited 92 patients with mild-to-moderate active Crohn's disease, dividing them equally into two groups. The treatment group received herb-partitioned moxibustion combined with true acupuncture, while the control group received placebo moxibustion (using wheat bran instead of herbs) and superficial acupuncture at nonspecific points. Both groups were treated three times per week for 12 weeks, totaling 36 sessions, and were followed for an additional 24 weeks.

The principal indicator used to assess improvement was the Crohn's Disease Activity Index, a standardized scale that considers symptoms such as the number of liquid stools, abdominal pain, general well-being, and other factors. Laboratory tests, quality of life, endoscopic findings, and histologic analyses of intestinal tissue were also evaluated. Importantly, both patients and investigators remained blinded to the type of treatment received, ensuring greater reliability of the results.

The results were impressive and consistent. Both groups showed significant reductions in disease activity scores after treatment, but the group receiving true acupuncture demonstrated substantially greater improvements. In the treatment group, 74% of patients achieved clinical remission, compared with only 36% in the control group. Total treatment efficacy was 83.72% in the acupuncture group versus 40.48% in the placebo group.

More importantly, improvements in the treatment group remained stable throughout the 24-week follow-up period, whereas those in the control group were not sustained. Regarding laboratory tests, patients treated with acupuncture showed a significant rise in hemoglobin levels — countering the anemia common in these patients — and a substantial decrease in C-reactive protein, an inflammatory marker. Quality of life also improved significantly more in the treatment group. Histologic analyses revealed that only the acupuncture group showed significant improvement in intestinal tissue architecture, suggesting a real anti-inflammatory effect of the therapy.

For patients with Crohn's disease, these results offer a hopeful perspective. Acupuncture and moxibustion demonstrated not only the ability to reduce disease symptoms but also to produce lasting improvements that persisted months after treatment ended. Unlike many conventional drugs, the study reported only two mild adverse events in 92 patients, demonstrating an excellent safety profile. For healthcare professionals, the findings suggest that acupuncture may be a valuable adjuvant therapy, especially given that it was effective across different patient subgroups — regardless of sex, disease severity, corticosteroid use, or location of intestinal lesions.

Subgroup analysis demonstrated consistent benefits across all categories evaluated. The investigators also explored mechanisms of action, suggesting that acupuncture may modulate the inflammatory response by regulating cytokines such as tumor necrosis factor alpha, protecting the intestinal barrier, and reducing programmed cell death in the intestinal epithelium.

The study has some important limitations to consider. During the follow-up period, only the principal efficacy indicator was evaluated, omitting quality of life measures and laboratory tests for that period. Additionally, anxiety and depression levels were not measured — important aspects in Crohn's disease. The control methodology, although widely accepted, may have limitations, since even superficial acupuncture can produce some therapeutic effects.

The heat generated by moxibustion may also have affected nearby acupuncture points in the control group, potentially reducing the differences between groups.

In summary, this study provides robust scientific evidence that herb-partitioned moxibustion combined with acupuncture represents an effective and safe therapeutic option for patients with mild-to-moderate Crohn's disease. The benefits observed went beyond the placebo effect, offering significant and sustained clinical improvements. For patients facing the challenges of conventional treatments, this ancient approach — now scientifically validated — may represent a valuable alternative or complement to the available therapeutic arsenal. It is essential that interested patients seek qualified acupuncture practitioners and maintain regular medical follow-up, integrating this therapy into the overall treatment plan for the disease.